Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

154 results about "Myostatin" patented technology

Myostatin (also known as growth differentiation factor 8, abbreviated GDF-8) is a myokine, a protein produced and released by myocytes that acts on muscle cells' autocrine function to inhibit myogenesis: muscle cell growth and differentiation. In humans it is encoded by the MSTN gene. Myostatin is a secreted growth differentiation factor that is a member of the TGF beta protein family.

Novel activin receptor and uses thereof

The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also provided.
Owner:AMGEN INC

Methods for treating fatty liver disease

In certain aspects, the present invention provides compositions and methods for treating fatty liver disease by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. A variety of hepatic and metabolic disorders may be improved by treating fatty liver disease.
Owner:ACCELERON PHARMA INC

Antibodies That Bind Myostatin, Compositions And Methods

There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.
Owner:AMGEN INC

Use of passive myostatin immunization

InactiveUS20020127234A1Increase in breast muscle and thigh muscle and testis and heart weightPromote growth ratePeptide/protein ingredientsVertebrate antigen ingredientsMyostatinBiomedical engineering
A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization is provided.
Owner:RGT UNIV OF MINNESOTA

Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Anti-myostatin antibodies

A neutralizing epitope is identified within amino acids 40-64 of the mature form of human myostatin. Antibodies that bind this epitope fall within the scope of the invention and may be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammals.
Owner:ELI LILLY & CO

Metalloprotease activation of myostatin, and methods of modulating myostatin activity

InactiveUS20050043232A1Increased and decreased cleavage activityReduces and inhibits metalloprotease mediated activationPeptide/protein ingredientsHydrolasesMyostatinBiological body
It has been determined that metalloprotease cleavage of a myostatin pro peptide results in activation of a latent inactive myostatin to an active form. Accordingly, methods of identifying agents that modulate metalloprotease mediated activation of myostatin are provided, as are agents identified using such methods. Also provided are methods of modulating muscle growth in an organism by increasing or decreasing metalloprotease mediated cleavage of a myostatin pro peptide.
Owner:WISCONSIN ALUMNI RES FOUND +2

Method for knocking out MSTN (myostatin) genes in targeted manner by utilizing CRISPR-Cas9

The invention discloses a method for knocking out MSTN (myostatin) genes in a targeted manner by utilizing CRISPR-Cas9. According to the method, multiple species are subjected to homology comparison, two pairs of MSTN gene target sequences are selected, two pairs of DNA double strands which have the sequences different from the target sequences, the same expression protein and the same BsmBi sticky ends are synthesized according to the design principle of PAM of gRNA, the double strands are connected with pPDNA330 plasmids, a recombinant vector carrying MSTN homologous genes of multiple species is obtained and is used for detecting the gene knockout efficiency with a fluorescent protein expression method, carrier-transfected receptor cells, having higher knockout efficiency, of multiple species are selected, gene knockout and verification are performed, and simple, efficient and accurate gene knockout on the MSTN genes of the multiple species is completed.
Owner:GUANGXI ZHUANG AUTONOMOUS REGION BUFFALO INST

Methods for detection of mutations in myostatin variants

Methods for detecting allelic variants of the myostatin (growth and differentiation factor-8) gene are provided. Specifically provided are methods of identifying subjects having or having a predisposition for increased muscle mass as compared to subjects having wild-type myostatin. Increased muscle mass is particularly desirable for identification of animals used to produce food products, including bovine, porcine, ovine, avian and piscine species.
Owner:THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

Myostatin inhibitor enhancement of musculoskeletal repair

The methods and compositions of this invention provide a means of regenerating injured musculoskeletal tissue by inhibition of myostatin function. The invention provides methods of treating a nonunion fracture in an individual comprising delivering to the fracture via a delivery system comprising biodegradable hydrogel, a pharmacological amount of myostatin propeptide effective to inhibit myostatin function. The invention also teaches compositions useful for the treatment of non-union fracture in an individual, said compositions comprising a pharmacological amount of myostatin propeptide effective to inhibit myostatin function; and a delivery system for delivering said myostatin propeptide to said fracture, wherein the delivery system comprises a biodegradable hydrogel or biodegradable nanobeads.
Owner:GEORGIA HEALTH SCI UNIV RES INST

Antisense composition and method for treating muscle atrophy

A method and compound for treating skeletal muscle mass deficiency in a human subject are disclosed. The composition is an oligomer of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5′ exocyclic carbon of an adjacent subunit, contains between 10-40 nucleotide bases, has a base sequence effective to hybridize to an expression-sensitive region of processed or preprocessed human myostatin RNA transcript, identified, in its processed form, by SEQ ID NO:6, and is capable of uptake by target muscle cells in the subject. In practicing the method, the compound is administered in an amount and at a dosage schedule to produce an overall reduction in the level of serum myostatin measured in the patient, and preferably to bring the myostatin level within the a range determined for normal, healthy individuals.
Owner:AVI BIOPHARMA

Variant activin receptor polypeptides and uses thereof

The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Oligomers

Certain disclosed oligomers induce exon skipping during processing of myostatin pre-mRNA. The oligomers may be in a vector or encoded by the vector. The vector is used for inducing exon skipping during processing of myostatin pre-mRNA. A therapeutically effective amount of the oligomer may be administered to a subject patient such that exon skipping during processing of myostatin pre-mRNA is induced. The administration to a subject may be used in order to increase or maintain muscle mass, or slowing degeneration of muscle mass in the subject. The administration to a subject may ameliorate muscle wasting conditions, such as muscular dystrophy. Examples of such muscular dystrophies which may be so treated include Becker's muscular dystrophy, congenital muscular dystrophy, Duchenne muscular dystrophy, distal muscular dystrophy, Emery-Dreifuss muscular dystrophy, facioscapulohumeral muscular dystrophy (FSHD), limb-girdle muscular dystrophy, myotonic muscular dystrophy, and oculopharyngeal muscular dystrophy
Owner:ROYAL HOLLOWAY & BEDFORD NEW COLLEGE

CRISPER-Cas9-system-mediated sheep MSTN (myostatin) gene knock-out and exogenous gene site-specific integration method

The invention relates to a CRISPER-Cas9-system-mediated sheep MSTN (myostatin) gene knock-out and exogenous gene site-specific integration method. The method comprises the following steps: establishing a CRISPER-Cas9-system-based gRNA (guide ribonucleic acid) expression vector according to a sheep MSTN gene sequence, establishing an exogenous-gene-containing donor plasmid capable of being integrated into a host genome according to the acting site of the gRNA, and transforming the optimized CRISPER-Cas9 vector, the gRNA expression vector and the linearized donor plasmid into sheep fibroblasts, thereby obtaining the sheep MSTN gene knock-out and exogenous gene site-specific integrated cells. The CRISPER-Cas9-mediated targeted vector provides a simple quick safe way for sheep MSTN gene knock-out and exogenous gene site-specific integration, thereby greatly enhancing the screening efficiency of the transgenic cell line. The method can screen the site-specific integrated exogenous gene cell line without adding any selection marker, thereby greatly enhancing the safety of the transgenic animals and having important value for sheep genetic breeding.
Owner:INNER MONGOLIA UNIVERSITY

Anti-myostatin antibodies

Anti-myostatin antibodies are identified that are characterized as having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof. The antibodies of the invention are useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species.
Owner:ELI LILLY & CO

Variant activin receptor polypeptides and uses thereof

ActiveUS20120328595A1Size of tumor massOrganic active ingredientsHydrolasesDiseaseMyostatin
The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.
Owner:AMGEN INC

Use of Myostatin (Gdf-8) Antagonists for Improving Wound Healing and Preventing Fibrotic Disease

The present invention relates to a method of improving wound healing in a human or animal patient by inhibiting the activity of myostatin (GDF-8) using one or more myostatin antagonists. The present invention also relates to a method of treating fibrotic diseases or disorders comprising administering a myostatin antagonist.
Owner:ORICO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products